Our companies

Empowering change through science

We are full life cycle investors supporting scientists and entrepreneurs at any stage where we identify opportunity, from academic programs in need of industry sponsorship all the way to mature publicly traded companies.

Alcyone Therapeutics

Pioneering next-generation precision gene-based therapies for complicated disorders of the central nervous system (CNS). We integrate innovations in neuroscience, gene therapy, precision dosing and delivery, and manufacturing to deliver transformative therapies to patients.

Disease/TX area
Rare Disease, CNS
Ancora Heart

A medical device company dedicated to providing new treatment options for people with heart failure (HF). The company’s proprietary AccuCinch® Ventricular Restoration System is the first completely percutaneous device designed to restore the enlarged left ventricle of the heart, thereby addressing the fundamental issue in the progression of systolic heart failure.

Disease/TX area
Cardiovascular
Armo BioSciences

An immuno-oncology company with a pipeline of novel interleukins for cancer.

Disease/TX area
Cancer
Avidity Biosciences

We are delivering a new class of RNA therapeutics - AOCs - which combine the specificity of monoclonal antibodies and the precision of oligonucleotides. Through integrating these proven technologies, our AOC platform is able to deliver to previously inaccessible tissue and cell types and more effectively target the underlying genetic drivers of diseases. With an agile and diverse team, we are advancing and expanding our pipeline programs to offer treatment options for patients and their families.

Disease/TX area
Myotonic Dystrophy
Beta Bionics

The developer of the iLet®, a revolutionary bionic pancreas driven by machine-learning artificial intelligence to autonomously control blood sugar.

Disease/TX area
Type 1 Diabetes
CinCor Pharma

A clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, baxdrostat (CIN-107), for the treatment of hypertension and other cardio-renal diseases. It is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland.

Disease/TX area
Cardiovascular
Encoded

Developing life-changing therapeutics for severe genetic disorders that are not addressable with existing gene therapy approaches.

GH Research

A clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Disease/TX area
Neurology
Immunocore Holdings PLC

A London-based company with an immuno-oncology platform technology called ImmTACs. ImmTACs enable the potent targeting of intracellular cancer antigens with controlled pharmacology.

Disease/TX area
Cancer, Autoimmune, Infection
JiXing

Backed by RTW Investments, JiXing is a privately held, leading Shanghai-based biotechnology company committed to bringing innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases.

Disease/TX area
Cardiovascular, Ophthalmology
Founded
2020
Magnolia Medical Technologies

Developing, manufacturing, and marketing innovative blood and bodily fluid collection devices to facilitate significant improvements in the accuracy, consistency, and predictability of critical laboratory tests. Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT™) and Device (ISDD®) for blood culture collection and contamination prevention.

Disease/TX area
Inflammatory, Sepsis
Milestone Pharmaceuticals Inc

A late-stage biopharmaceutical company developing a drug intended to provide outpatient treatment of paroxysmal supraventricular tachycardia (PSVT).

Disease/TX area
Cardiovascular
NiKang

A preclinical stage biotech company discovering and developing innovative small molecule oncology medicines.

Disease/TX area
Oncology
Orchestra BioMed

The developer of Virtue SEB, a sirolimus eluting balloon for treatment of coronary and peripheral arterial disease.

Disease/TX area
Cardiovascular
Prometheus Biosciences Inc

Discovering and developing novel therapeutic and companion diagnostic products for the diagnosis and treatment of inflammatory bowel disease (IBD).

Disease/TX area
IBD
Rocket Pharmaceuticals Inc

Bringing hope and relief to patients with undertreated rare diseases through the development and commercialization of curative first-in-class gene-modified cell therapies.

Disease/TX area
Rare pediatric diseases
Founded
2015
Tarsus

Focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions such as Demodex blepharitis.

Disease/TX area
Ophthalmology
Tenaya

A biotechnology company with a mission to discover, develop, and deliver curative therapies that address the underlying causes of heart disease.

Disease/TX area
Cardiovascular
Umoja Biopharma

Developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.

Disease/TX area
Oncology
Ventyx

Advancing a pipeline of novel small molecule therapeutics with a best-in-class potential for patients with inflammatory and autoimmune diseases.

Disease/TX area
Inflammatory, Autoimmune
Visus

A clinical-stage pharmaceutical company developing presbyopia-correcting eye drop.

Disease/TX area
Ophthalmology
Yarrow

An RTW-incubated company developing antisense oligonucleotide (ASO) therapeutics for severe, genetically defined CNS diseases.

Disease/TX area
CNS
Founded
2021

The investments listed above include RTW funds’ investments in private companies that have had a liquidity event, or are investments of RTW Venture Fund Ltd. They do not include names of investments for which RTW is under non-disclosure obligations or in certain circumstances that are related to the protection of RTW’s competitive edge.

Explore

Our strategy
Key facts

Speak to a member of our team